{
  "id": "3f4d2e17dd1d44ff",
  "title": "BeOne Medicines Ltd .: BRUKINSA Delivers Landmark 74 % 6 - Year PFS in Patients with Treatment - Na\u00efve Chronic Lymphocytic Leukemia",
  "description": "20251208T134500Z",
  "content": "",
  "source": "finanznachrichten.de",
  "source_url": "https://www.finanznachrichten.de/nachrichten-2025-12/67173185-beone-medicines-ltd-brukinsa-delivers-landmark-74-6-year-pfs-in-patients-with-treatment-naive-chronic-lymphocytic-leukemia-004.htm",
  "published_at": "20251208T134500Z",
  "fetched_at": "2025-12-09T00:22:19.510482+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "Germany",
  "raw_data": {
    "url": "https://www.finanznachrichten.de/nachrichten-2025-12/67173185-beone-medicines-ltd-brukinsa-delivers-landmark-74-6-year-pfs-in-patients-with-treatment-naive-chronic-lymphocytic-leukemia-004.htm",
    "url_mobile": "",
    "title": "BeOne Medicines Ltd .: BRUKINSA Delivers Landmark 74 % 6 - Year PFS in Patients with Treatment - Na\u00efve Chronic Lymphocytic Leukemia",
    "seendate": "20251208T134500Z",
    "socialimage": "https://cts.businesswire.com/ct/CT?id=bwnews&sty=20251208674374r1&sid=gefi2&distro=ftp",
    "domain": "finanznachrichten.de",
    "language": "English",
    "sourcecountry": "Germany"
  }
}